VERVE THERAPEUTICS INC (VERV) Stock Price, Forecast & Analysis
USA - NASDAQ:VERV - US92539P1012 - Common Stock
VERV Key Statistics, Chart & Performance
The current stock price of VERV is 11.13 USD. In the past month the price decreased by -0.71%. In the past year, price increased by 50.41%.
VERV Latest News, Press Relases and Analysis
VERV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.96 | 383.31B | ||
| AMGN | AMGEN INC | 14.7 | 173.09B | ||
| GILD | GILEAD SCIENCES INC | 14.33 | 145.67B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.82 | 106.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.67 | 70.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 874.65 | 58.47B | ||
| INSM | INSMED INC | N/A | 39.59B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 9.25 | 22.69B | ||
| INCY | INCYTE CORP | 16.27 | 20.39B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.58 | 14.75B |
Related stock screener links
About VERV
Company Profile
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company is headquartered in Boston, Massachusetts and currently employs 274 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The Company’s lead programs include VERVE-102, VERVE-201, and VERVE-301, which target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE- 201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels.
Company Info
VERVE THERAPEUTICS INC
201 Brookline Avenue, Suite 601
Boston MASSACHUSETTS US
CEO: Sekar Kathiresan
Employees: 255
Phone: 19785013026
VERVE THERAPEUTICS INC / VERV FAQ
What does VERV do?
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company is headquartered in Boston, Massachusetts and currently employs 274 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The Company’s lead programs include VERVE-102, VERVE-201, and VERVE-301, which target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE- 201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels.
Can you provide the latest stock price for VERVE THERAPEUTICS INC?
The current stock price of VERV is 11.13 USD. The price increased by 0.27% in the last trading session.
Does VERVE THERAPEUTICS INC pay dividends?
VERV does not pay a dividend.
How is the ChartMill rating for VERVE THERAPEUTICS INC?
VERV has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for VERVE THERAPEUTICS INC?
VERVE THERAPEUTICS INC (VERV) operates in the Health Care sector and the Biotechnology industry.
VERV Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to VERV. When comparing the yearly performance of all stocks, VERV is one of the better performing stocks in the market, outperforming 95.29% of all stocks.
VERV Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VERV. While VERV has a great health rating, there are worries on its profitability.
VERV Financial Highlights
Over the last trailing twelve months VERV reported a non-GAAP Earnings per Share(EPS) of -2.11. The EPS increased by 26.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.47% | ||
| ROE | -38.23% | ||
| Debt/Equity | 0 |
VERV Forecast & Estimates
14 analysts have analysed VERV and the average price target is 13.26 USD. This implies a price increase of 19.14% is expected in the next year compared to the current price of 11.13.
For the next year, analysts expect an EPS growth of -8.2% and a revenue growth 93.9% for VERV